A Study Evaluating the Bioequivalence of VIAject®7 Compared to VIAject®25 and Comparing the Pharmacokinetic and Pharmacodynamic Properties of VIAject®7 to Insulin Lispro in Subjects With Type 1 Diabetes Mellitus

Diabetes Mellitus Clinical Trial

Official title:

A Single Center, Double Blind, Randomized Crossover Study Evaluating the Bioequivalence of VIAject®7 Compared to VIAject®25 and Comparing the Pharmacokinetic and Pharmacodynamic Properties of VIAject®7 to Insulin Lispro in Subjects With Type 1 Diabetes Mellitus

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01235039
• Other study ID #: VIAject -030J
• Status: Completed
• Phase: Phase 1/Phase 2
• First received: November 2, 2010
• Last updated: July 28, 2015
• Start date: July 2009
• Est. completion date: September 2009

Study information

• Verified date: July 2015
• Source: Biodel
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug AdministrationGermany: Federal Institute for Drugs and Medical Devices
• Study type: Interventional

Clinical Trial Summary

The primary objective of this study is to test for bioequivalence of VIAject®7 and VIAject®25 and to compare the pharmacokinetic/Pharmacodynamic/tolerability characteristics of VIAject®7 with those of VIAject®25 and insulin lispro.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 43
• Est. completion date: September 2009
• Est. primary completion date: September 2009
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 19 Years to 65 Years

Eligibility

Inclusion Criteria:

• Age: =19 to =65 years

• Body Mass Index: =18 - =28 kg/m2

• Diagnosed with Type 1 Diabetes Mellitus for at least 1 year

• Insulin antibody less than or equal to 10 µU/mL at screening

• Non-smoker, defined as no nicotine consumption for at least one year.

• Signed and dated informed consent obtained before any trial-related activities. (Trial-related activities are any procedure that would not have been performed during normal management of the subject)

Exclusion Criteria:

• Type 2 Diabetes Mellitus

• C-peptide value of >1.0 ng/mL

• HbA1c value of > 10.0%

• History of hypersensitivity to any of the components in the study medication

• History of severe or multiple allergies

• Treatment with any other investigational drug in the last 3 months before study entry

• Any systemic treatment with drugs known to interfere with glucose metabolism such as systemic corticoids, non-selective beta-blockers, and monoamine oxidase (MAO) inhibitors within 3 months prior to randomization.

• Changes (type of drug or dose) in concomitant medication other than insulin or insulin analogues in the last 3 weeks prior to randomization.

• Use of non-prescription drugs, except routine vitamins, within 3 weeks prior to the first dose of the test drug. Occasional use of paracetamol/acetaminophen is permitted.

• Progressive disease likely to prove fatal (e.g. malignancies)

• Current drug or alcohol abuse, or a history of drug or alcohol abuse which in the opinion of the Investigator will impair subject safety or protocol compliance

• Significant cardiovascular, respiratory, gastrointestinal, hepatic, renal, neurological, psychiatric and/or hematological disease as evaluated by the Investigator

• Clinically significant abnormal hematology or biochemistry screening tests, as judged by the Investigator. In particular, subjects with elevated liver enzymes (AST or ALT >2 times the upper limit of normal) or impaired renal function (serum creatinine values above the upper limit of normal) will not be allowed to enter the trial.

• Any serious systemic infectious disease during the four weeks prior to the first dose of study drug, as judged by the Investigator.

• History of any illness that, in the opinion of the Investigator, might confound the results of the trial or pose a risk in administering the trial drug to the subject. In particular, subjects with significant cardiovascular disease, anemia (hemoglobin below the lower limit of normal) or hemoglobinopathy will not be allowed to enter the trial.

• Blood donation within the last 30 days

• A woman who is lactating

• Pregnant women or women intending to become pregnant during the study

• A sexually active woman - not using adequate contraceptive methods (adequate contraceptive measures include: implants, injectables, combined oral contraceptives, hormonal intrauterine device [IUD], sexual abstinence or vasectomized partner)

• Positive serology for HIV, Hepatitis B or Hepatitis C

• Abnormal ECG, safety lab or physical examination results that are deemed clinically significant by the Investigator

• Lack of compliance or other reasons which, in the opinion of the Investigator, prevent the participation of the subject in the study.

Study Design

Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Diabetes Mellitus
• Diabetes Mellitus, Type 1

Intervention

Drug:
• VIAject®25
Two vial presentation for reconstitution and single dose of 12 IU subcutaneous injection and 25 IU/mL
• VIAject®7
One vial presentation and single dose of 12 U for subcutaneous injection and 100 IU/mL
• Insulin Lispro
One vial presentation and single dose of 12 IU for subcutaneous injection and 100 IU/mL

Locations

Country	Name	City	State
Germany	Profil Institut für Stoffwechselforschung GmbH	Neuss

Sponsors (1)

Lead Sponsor	Collaborator
Biodel

Country where clinical trial is conducted

Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Serum insulin concentration	Area under the serum insulin concentration curve for the time interval 0-480 min (AUC-INS 0-480) and maximum serum insulin concentration (C-INS max) (VIAject®7and VIAject®25 only)	0-480 minutes	Yes
Secondary	Serum insulin concentration	AUC-INS: area under the serum insulin concentration curve for the time period 0-240 minutes; AUC-INS: area under the serum insulin concentration curve for the time period 0 (VIAject® dosing) to the time when the insulin value returns to baseline	0-240 minutes	Yes
Secondary	Glucose infusion rate	•AUCGIR: area under the glucose infusion rate curve for the following time periods: 0-240, 0-480 minutes	Between 0-240 minutes and 0-480 minutes	Yes